Home » ALLERGAN ANNOUNCES FINAL EXTENSION OF INAMED EXCHANGE OFFER AND AMENDMENT TO MERGER AGREEMENT
ALLERGAN ANNOUNCES FINAL EXTENSION OF INAMED EXCHANGE OFFER AND AMENDMENT TO MERGER AGREEMENT
Allergan, Inc. today announced that it is extending the expiration date of its exchange
offer for all outstanding shares of common stock of Inamed Corporation. All conditions
to the completion of the exchange offer currently are satisfied. However, Allergan
is extending the offer pursuant to its one-time right under its merger agreement
with Inamed to extend the offer for up to five business days to seek valid tenders
representing at least 90% of the outstanding Inamed common stock so that it can
complete the acquisition through a short-form merger under Delaware law.
Genetic
Engineering News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May